BOTHELL, Wash., Feb. 14 /PRNewswire-FirstCall/ -- Lumera Corporation
(Nasdaq: LMRA) and The Institute for Systems Biology (ISB) have agreed to
collaborate in the development of a high-throughput, label-free detection
platform designed to revolutionize proteomics research.
The technology platform consists of Lumera's ProteomicProcessor(TM) and
NanoCapture(TM) Array technology. The ProteomicProcessor(TM) tool reads
Lumera's high density NanoCapture(TM) Microarrays in real-time, without the
use of molecular labels. By combining these technologies, researchers will be
able to isolate, compile and process vast amounts of data at high-speeds to
accelerate proteomic research.
Protein-protein, protein-drug, and protein-DNA interactions can be
measured with the new system. Real-time kinetics measurements are provided
for the binding interactions from complex mixtures on thousands of
user-defined spots on the high density NanoCapture(TM) Microarrays.
"We are extremely pleased to work with ISB on this exciting proteomics
project. We believe that combining NanoCapture(TM) arrays with real-time
detection will revolutionize the way and the speed at which proteomics
research is done," said Lumera Chief Executive Officer Tom Mino. "Our
intention is to bring this technology to market as a user-definable, open
platform product family as quickly as possible."
"By eliminating the need for labels in a high throughput format, Lumera
has removed one of the major road blocks in protein research," said Stephen
Lasky, ISB's Director of Technology Development. "Lumera's
ProteomicProcessor(TM) has the potential to give us the capability to look at
large networks of binding interactions while, at the same time, providing us
with specific interaction kinetics of each individual binding event," Lasky
continued. "Until now, there has been no feasible method of doing anything
like this on a systems-wide level."
Lumera is an emerging leader in the field of nanotechnology. The company
designs proprietary molecular structures and polymer compounds for a broad
range of bioscience, electro-optic, and specialty nanotechnology applications.
The company also has developed proprietary processes for fabricating such
devices. For more information, please visit http://www.lumera.com/.
Certain statements contained in this release are forward-looking
statements that involve a number of risks and uncertainties. Factors that
could cause actual results to differ materially from those projected in the
company's forward-looking statements include the following: market acceptance
of our technologies and products; our ability to obtain financing; our
financial and technical resources relative to those of our competitors; our
ability to keep up with rapid technological change; government regulation of
our technologies; our ability to enforce our intellectual property rights and
protect our proprietary technologies; the ability to obtain additional
contract awards and to develop partnership opportunities; the timing of
commercial product launches; the ability to achieve key technical milestones
in key products; and other risk factors identified from time to time in the
company's SEC reports, including in its registrations statement on Form S-1,
dated July 22, 2004 and its Quarterly Reports on Form 10-Q.
SOURCE Lumera Corporation